GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
Sanofi
Posted inAutoimmune Diseases, Metabolism, New Drugs, Regulatory
Awiqli: Basal Insulin Once a Week
Novo Nordisk invented insulin icodec, a very patient-friendly ultra-long-acting insulin.
Posted inAutoimmune Diseases, Clinical Trials
Apogee Therapeutics: Treating Eczema With Two Injections per Year
Biologic treatment for atopic dermatitis reaches a new level of convenience.
Posted inCardiology, Clinical Trials, In the Pipeline, Metabolism
Enlicitide: Very Strong Pill Against ‘Bad’ Cholesterol
The oral drug by Merck & Co. smashes all competitors for the treatment and prevention of atherosclerosis.
Posted inInfections, New Drugs, Regulatory
Beyfortus: Effective Protection for Infants Against Respiratory Syncytial Virus
One injection of nirsevimab reliably protects newborns against the development of RSV-associated lower respiratory tract infections.
Posted inClinical Trials, In the Pipeline, Metabolism
Most Effective Weight Loss Drugs: Present and Future
Modern pharmacological ways to combat obesity.
Posted inAutoimmune Diseases, Clinical Trials, Neuroscience
Ublyxi: Highly Effective Drug for Multiple Sclerosis
Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.